Zoetis Inc. (VIE:ZOTS)

Market Cap	43.12B -36.0%
Revenue (ttm)	8.06B +2.3%
Net Income	2.28B +7.5%
EPS	5.13 +10.1%
Shares Out	n/a
PE Ratio	18.94
Forward PE	16.61
Dividend	1.76 (1.72%)
Ex-Dividend Date	Jan 20, 2026

Volume	n/a
Average Volume	3
Open	100.60
Previous Close	101.42
Day's Range	100.52 - 101.98
52-Week Range	98.90 - 150.56
Beta	n/a
RSI	47.24
Earnings Date	May 7, 2026

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 14,500
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: ZOTS

Financial Performance

In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.

Financial numbers in USD